Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis The ARCADIA Multicenter Randomized Controlled Trial

Ruggenenti, Piero; Podesta, Manuel Alfredo; Trillini, Matias; Perna, Annalisa; Peracchi, Tobia; Rubis, Nadia; Villa, Davide; Martinetti, Davide; Cortinovis, Monica; Ondei, Patrizia; Condemi, Carmela Giuseppina; Guastoni, Carlo Maria; Meterangelis, Agnese; Granata, Antonio; Mambelli, Emanuele; Pasquali, Sonia; Genovesi, Simonetta; Pieruzzi, Federico; Bertoli, Silvio Volmer; Del Rosso, Goffredo; Garozzo, Maurizio; Rigotti, Angelo; Pozzi, Claudio; David, Salvatore; Daidone, Giuseppe; Mingardi, Giulio; Mosconi, Giovanni; Galfre, Andrea; Longhena, Giorgio Romei; Pacitti, Alfonso; Pani, Antonello; Godoy, Jorge Hidalgo; Anders, Hans-Joachim und Remuzzi, Giuseppe (2021): Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis The ARCADIA Multicenter Randomized Controlled Trial. In: Clinical Journal of the American Society of Nephrology, Bd. 16, Nr. 4: S. 575-587

Abstract

Background and objectives Renin-angiotensin system (RAS) inhibitors reduce cardiovascular morbidity and mortality in patients with CKD. We evaluated the cardioprotective effects of the angiotensin-converting enzyme inhibitor ramipril in patients on maintenance hemodialysis. Design, setting, participants, & measurements In this phase 3, prospective, randomized, open-label, blinded end point, parallel, multicenter trial, we recruitedpatientsonmaintenance hemodialysiswithhypertensionand/or left ventricular hypertrophy from 28 Italian centers. Between July 2009 and February 2014, 140 participants were randomized to ramipril (1.25-10 mg/d) and 129 participants were allocated to non-RAS inhibition therapy, both titrated up to themaximally tolerated dose to achieve predefined target BP values. The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the single components of the primary end point, new-onset or recurrence of atrial fibrillation, hospitalizations for symptomatic fluid overload, thrombosis or stenosis of the arteriovenous fistula, and changes in cardiac mass index. All outcomes were evaluated up to 42 months after randomization. Results At comparable BP control, 23 participants on ramipril (16%) and 24 on non- RAS inhibitor therapy (19%) reached the primary composite end point (hazard ratio, 0.93;95% confidence interval, 0.52 to 1.64;P=0.80). Ramipril reduced cardiac mass index at 1 year of follow-up (between- group difference in change from baseline: 216.3g/m(2);95% confidence interval, 229.4 to23.1), butdidnot significantlyaffect the other secondaryoutcomes. Hypotensive episodes were more frequent in participants allocated to ramipril than controls (41% versus 12%). Twenty participants on ramipril and nine controls developed cancer, including six gastrointestinalmalignancies on ramipril (four were fatal), compared with none in controls. Conclusions Ramipril did not reduce the risk of major cardiovascular events in patients on maintenance hemodialysis.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1555-9041
• Sprache: Englisch